Last reviewed · How we verify
GSK933776 for SQ administration — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK933776 for SQ administration (GSK933776 for SQ administration) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK933776 for SQ administration TARGET | GSK933776 for SQ administration | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK933776 for SQ administration CI watch — RSS
- GSK933776 for SQ administration CI watch — Atom
- GSK933776 for SQ administration CI watch — JSON
- GSK933776 for SQ administration alone — RSS
Cite this brief
Drug Landscape (2026). GSK933776 for SQ administration — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk933776-for-sq-administration. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab